ストックスクリーナーアプリを入手
11.91
0.68%
0.08
プレマーケット:
12.09
0.18
+1.51%
Intellia Therapeutics Inc (NTLA) 最新ニュース
NTLA|Intellia Therapeutics Inc|Price:11.910|Chg%:+0.080 - TradingKey
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
Intellia (NTLA) Q2 2026 Earnings Call Transcript - The Globe and Mail
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Wasatch Advisors LP Sells 134,215 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics Stock Short Interest Falls to 39.57% - Quiver Quantitative
Intellia Therapeutics, Inc. $NTLA Shares Acquired by Royal Bank of Canada - MarketBeat
(NTLA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Research Analysts Offer Predictions for NTLA FY2026 Earnings - MarketBeat
Intellia Therapeutics Insider Buyers See Boost After Market Cap Rose US$168m - Moomoo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
Equities Analysts Issue Forecasts for NTLA Q2 Earnings - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Issues Earnings Results - MarketBeat
Bank of America Securities Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Intellia Therapeutics (NTLA) Stock Rises As Pipeline Progress Lifts Sentiment - Sahm
NTLA SWOT Analysis: Financial Resilience Amidst Clinical Advancements Revealed in 10-Q Filing - GuruFocus
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
Intellia Therapeutics Inc earnings matched, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues - Yahoo Finance
State Street (NTLA) stake: 9.23M Intellia Therapeutics shares in 13G filing - Stock Titan
Intellia upgraded at Evercore ISI on nex-z hypothesis (NTLA:NASDAQ) - Seeking Alpha
Intellia Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit - Yahoo Finance
Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring Potential 127.65% Upside with CRISPR Innovations - DirectorsTalk Interviews
Will Intellia’s (NTLA) Narrowing Losses and Heavy R&D Spend Shift Its Risk Reward Narrative? - Yahoo Finance
Intellia Therapeutics Q2 Earnings Call Highlights - MarketBeat
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... By GuruFocus - Investing.com Canada
Intellia Therapeutics, Inc. Stock 12‑Month Price Target Cut to $25.56, Implies 133% Upside - TradingView
Intellia Therapeutics 2Q 2026: Revenue $7.7M, Net loss $106.6M, EPS $(0.80) — 10-Q Summary - TradingView
[10-Q] Intellia Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Intellia Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlig - GuruFocus
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... - Yahoo Finance
Form 8K Intellia Therapeutics Inc For: 6 August By Investing.com - Investing.com South Africa
Earnings call transcript: Intellia posts Q2 2026 revenue miss as shares slip premarket - Investing.com
Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating - marketscreener.com
Intellia Therapeutics Inc earnings matched, revenue fell short of estimates - Investing.com
INTELLIA THERAPEUTICS, INC. reports results for the quarter ended June 30Earnings Summary - TradingView
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Intellia Therapeutics reports Q2 2026 net loss of $106.6M, $628.4M cash; positive Phase 3 data for lonvo-z - TradingView
Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q2 Revenue $7.7M, Vs. FactSet Est of $13.0M - Moomoo
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Intellia Therapeutics
Intellia Therapeutics Q2 Operating Expenses U - moomoo.com
Intellia plans first-half 2027 U.S. launch if FDA approves hereditary angioedema treatment - Stock Titan
Dimensional Fund Advisors LP Increases Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Arrowstreet Capital Limited Partnership Makes New Investment in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 6 - moomoo.com
Intellia Sets Aug. 6 Webcast for Second-Quarter Business Update - Stock Titan
Intellia: Phase 3 HAELO Win Doesn't Fix The Commercial Problem - Seeking Alpha
Intellia Therapeutics Inc (NTLA) Cash Flow - TradingKey
Intellia Therapeutics CFO sells $91,248 in stock By Investing.com - Investing.com UK
Form 4 Intellia Therapeutics Inc For: 24 July By Investing.com - Investing.com Nigeria
Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dulac Edward J III - Moomoo
Intellia Therapeutics CFO sells $91,248 in stock - Investing.com
Intellia Therapeutics (NTLA) CFO logs 8,111-share sell-to-cover tax trade - Stock Titan
Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout | AI
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):